You are here » Home » Companies » Company Overview » DIL Ltd

DIL Ltd.

BSE: 506414 Sector: Health care
NSE: N.A. ISIN Code: INE225B01013
BSE LIVE 15:40 | 19 Sep 663.50 -6.30
(-0.94%)
OPEN

671.00

HIGH

671.00

LOW

641.10

NSE 05:30 | 01 Jan Stock Is Not Traded.
OPEN 671.00
PREVIOUS CLOSE 669.80
VOLUME 3229
52-Week high 899.00
52-Week low 590.00
P/E
Mkt Cap.(Rs cr) 152
Buy Price 0.00
Buy Qty 0.00
Sell Price 663.50
Sell Qty 70.00
OPEN 671.00
CLOSE 669.80
VOLUME 3229
52-Week high 899.00
52-Week low 590.00
P/E
Mkt Cap.(Rs cr) 152
Buy Price 0.00
Buy Qty 0.00
Sell Price 663.50
Sell Qty 70.00

DIL Ltd. (DIL) - Company History

Promoted by a technocrat, D V K Raju, Duphar-Interfran (DIL) was incorporated in May '51 as International Franchises Pvt Ltd. In the initial years, the company manufactured and sold toothpaste, anti-septic lotion and pharmaceutical specialities on a loan-licence basis. It entered into collaborations with Philips-Duphar, Amsterdam (Solvay Duphar), and the Crookes Laboratories, London. These collaborators participated in the equity capital of the company to the extent of 25% each. The company changed its name to Crookes Interfran on 19 Apr.'63. In 1964, it entered into a collaboration with Solvay Duphar to manufacture vitamin D3. To associate fully with its research-oriented collaborators, in May '71, it changed its name to Duphar-Interfran. In 1976, it entered into another collaboration with Solvay Duphar to manufacture isoxypurine hydrochloride -- a vasodilator. In 1976, in compliance with the FERA, the foreign collaborators reduced thier stake to 38.86%. DIL came out with a rights issue in May '95 to augment long-term resources and working capital requirements. The company also sold its popular analgesic brand Crocin to Smithkline Beecham Pharmaceuticals. It also sold another OTC brand, Lacto-Calamine lotion to Nicholas Piramal to concentrate on the core business of ethical drugs. As per the Scheme of Arrangement, the pharma business of the company has been transferred to a new company called Duphar Pharma India. The Company has made investments in unutilised premises at Thane to create a commercial complex with modern facilities so that substantial portion of it can be let out to earn income. The successful entry of Annual Contract with Solvay Pharmaceuticals B V of Netherlands will definitely establish as a reliable contract research organization for Duphar Interfran Ltd. As mutual consent with Solvay Pharmaceuticals,Netherlands,the company has been permitted to continue with the name DUPHAR for a limited time. It has also been decided to change the name to DIL Limited from Duphar-Interfran Ltd. With the prior approval from Board the company has acquired 990,000 equity shares of Rs.10 each in Fermenta Biotech Ltd there by increase its holding to 83.71% comprising 16,57,500 equity shares. Subsequent to this FBL will henceforth be a subsidiary of Duphar Interfran Ltd.